YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, March 25 /PRNewswire-FirstCall/ -- Galil Medical, a global cryotherapy company, today announced that Martin J. Emerson has been appointed President and Chief Executive Officer. Galil Medical is a market leader in cryotherapy technology for the minimally invasive treatment of cancerous and non-cancerous tumours. Mr. Emerson is an experienced and successful medical device industry executive, and was most recently President and CEO of American Medical Systems (AMS). He will be replacing Chen Barir, who will continue to serve on the Galil Medical Board of Directors.
Chen Barir commented, “Galil Medical is very pleased to have been able to attract an executive with the leadership experience and stature of Marty Emerson. We are confident that Marty will be able to help Galil Medical sustain the growth that has been recorded since our December 2006 reorganisation and recapitalisation financing.”
“I am very excited to be joining Galil Medical,” said Mr. Emerson. “The company has developed innovative cryotherapy solutions to treat prostate cancer and renal tumours and has a promising product pipeline for the Women’s Health and Interventional Radiology markets. I look forward to working with the talented team to expand the opportunities for Galil Medical’s industry leading technology around the globe.”
Mr. Emerson has a strong track record of over 20 years of accomplishments in the medical device industry, most recently as President and Chief Executive Officer of AMS. During his tenure at AMS, he held executive roles including Vice President and General Manager of International, Executive Vice President of Global Sales and Marketing and Chief Operating Officer. Prior to joining AMS, he held senior roles in the overseas operations for several American-based companies including Baxter International and Boston Scientific.
About Galil Medical
Galil Medical develops, manufactures and markets innovative products utilising a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumours while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumours while protecting adjacent structures.
Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ: ELRN - News) and RDC Rafael Development Corporation, Ltd. For more information, please visit http://www.galilmedical.com
Pam Schwartz Communications Manager Galil Medical T: +972-4-909-3273 M: +972-52-625-4443 F: +972-4-959-1077 pam.schwartz@galilmedical.com
Source: Galil Medical
